There is increasing evidence for the therapeutic effectiveness of Interferon-alpha (IFN-alpha) in malignant diseases. However, the antitumor mechanisms of IFN-alpha are not known. Using two examples, hairy Cell leukemia (HCL) and renal cell cancer (RCC), it is shown that the requirements for successful IFN-alpha therapy of HCL and RCC are different. In HCL low doses of IFN-alpha are sufficient to treat the disease. The reduction of hairy cells in peripheral blood is detectable within the first week of treatment. The endogenous IFN-alpha production in these patients is impaired as demonstrated by the lack of IFN-alpha induction and by low levels of 2-5 oligoadenylate synthetase in peripheral blood mononuclear cells. A possible reason for deficient endogenous IFN-alpha production is the lack of monocytes in HCL patients. It is likely that therapy with low doses of IFN-alpha substitutes for the endogenous IFN-alpha deficiency. In RCC comparatively high doses of IFN-alpha are necessary for a clinical response. There may be differences between the effectiveness of natural and recombinant alpha interferons. High doses given within a week seem to be more important than high single doses, which therefore suggests the need of daily treatment. Responses of RCC to IFN-alpha therapy are usually seen several months after the beginning of therapy. These differences in the effectiveness of IFN-alpha therapy for HCL and RCC suggest that IFN-alpha acts differently in the treatment of each disease.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19880115)61:2<288::aid-cncr2820610217>3.0.co;2-0DOI Listing

Publication Analysis

Top Keywords

ifn-alpha
13
ifn-alpha therapy
12
doses ifn-alpha
12
endogenous ifn-alpha
12
antitumor mechanisms
8
hairy cell
8
cell leukemia
8
renal cell
8
cell cancer
8
therapy hcl
8

Similar Publications

HBV genotype A has two major subtypes, A1 (commonly in Africa) and A2 (commonly in Europe) with only 4% nucleotide differences. Individuals infected with these two subtypes appear to have different clinical manifestations and virologic features. Whether such a difference results from the virus or host has not been established.

View Article and Find Full Text PDF

Identification of serum IFN-α and BAFF levels as potential biomarkers of activity and severity in cutaneous lupus erythematosus.

J Invest Dermatol

January 2025

Sorbonne Université, Faculté de médecine, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Dermatologie et Allergologie, Hôpital Tenon, Paris, France; Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI PARIS), INSERM U1135, Paris, France.

View Article and Find Full Text PDF

Background: Understanding the interference patterns of respiratory viruses could be important for shedding light on potential strategies to combat these human infectious agents.

Objective: To investigate the possible interactions between adenovirus type 2 (AdV2), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A/H1N1 pandemic (H1N1pdm09) using the A549 cell line.

Methods: Single infections, co-infections, and superinfections (at 3 and 24 h after the first virus infection) were performed by varying the multiplicity of infection (MOI).

View Article and Find Full Text PDF

Plasmacytoid dendritic cells (pDCs) express Toll-like receptor 7 (TLR7) in the endosomes, recognize viral single-stranded RNA (ssRNA), and produce significant amounts of interferon (IFN)-α. Bovine lactoferrin (LF) enhances the response of IFN regulatory factors followed by the activation of IFN-sensitive response elements located in the promoter regions of the gene and IFN-stimulated genes in the TLR7 reporter THP-1 cells in the presence of R-848, a TLR7 agonist. In ex vivo experiments using human peripheral blood mononuclear cells, LF enhances IFN-α levels in the supernatant in the presence of R-848.

View Article and Find Full Text PDF

IFN alpha signaling drives hematopoietic stem cells malfunction under acute inflammation.

Int Immunopharmacol

January 2025

Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China. Electronic address:

Article Synopsis
  • Inflammation triggers the activation of hematopoietic stem cells (HSCs) via direct sensing of lipopolysaccharide (LPS) through toll-like receptor 4 (TLR4) and cytokine release.
  • The study found that LPS stimulation leads to the activation of the interferon alpha (IFNα) signaling pathway, resulting in both the activation and eventual exhaustion of HSCs.
  • Creatine, an inhibitor of IFNα, can prevent HSC activation and exhaustion caused by LPS, while a deficiency in the IFNα receptor (IFNAR) offers protection to HSCs during inflammation, indicating that LPS injuries HSCs through both direct and indirect pathways.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!